Ikibazo gihuza ibibazo · Hagati Urwego

AI mu mutekano wibiyobyabwenge hamwe na Pharmacovigilance Ikibazo

Ongera usuzume raporo mbi yibyabaye, gutahura ibimenyetso hamwe na code zisanzwe mubikorwa byo kugenzura umutekano wibiyobyabwenge byinjira mubicuruzwa.

Ikibazo 1 Bya 8

Niyihe ntego yibanze ya farumasi?

Reba buri kibazo8 ibibazo

Ibisubizo nibisobanuro bigaragara mugihe ufata ikibazo.

  1. Niyihe ntego yibanze ya farumasi?
    • Kumenya, gusuzuma, no gukumira ingaruka ziterwa n'imiti imaze gukoreshwa
    • Kwamamaza imiti mishya kubaganga
    • Gushiraho igiciro cyo kugurisha imiti
    • Gutegura ibipaki
  2. Muri sisitemu ya N2c2 yubuvuzi NLP yasohotse, ni ayahe makuru sisitemu yakuye mu nyandiko zerekana?
    • Only patients’ handwritten signatures
    • Medication and adverse-event concepts and their relations
    • Only final regulatory decisions
    • Only medicine prices
  3. Ni ubuhe buryo budasesenguye bugaragaza mububiko bubi?
    • Itandukaniro ryibiciro hagati yibiyobyabwenge nibiyobyabwenge rusange
    • Nibihe bitaro byatanze raporo nyinshi
    • Ibiyobyabwenge-byabaye byombi byavuzwe kenshi kuruta amahirwe yo kubara
    • Amatariki yo kurangiriraho imiti
  4. Ikigo cya Monitoring Uppsala kivuga ko VigiBase ari iki?
    • A database of randomized clinical-trial efficacy results only
    • A list of confirmed causal side effects for every medicine
    • A commercial catalogue of approved drug prices
    • The WHO global database of reported adverse events for medicines and vaccines
  5. Niki MedDRA ikoreshwa mumiyoboro ya farumasi?
    • Amagambo asanzwe yubuvuzi ya coding reaction nibisabwa
    • Ikirango cyo gupakira imiti
    • Porogaramu itegura abaganga
    • Ubwoko bwa scaneri ya MRI
  6. Which sequence does UMC describe in its signal-management process?
    • Diagnosis, prescription, dispensing, billing and discharge
    • Detection, validation, prioritisation, assessment and communication
    • Data collection, automatic causality decision, recall and litigation
    • Model training, deployment, billing and marketing
  7. How should a high disproportionality score in a spontaneous-report database be interpreted?
    • As a population incidence rate for all patients
    • As a confirmed causal adverse reaction
    • As a statistical signal for further assessment, not proof that the drug caused the event
    • As proof that no other factor contributed
  8. Which four elements satisfy the minimum ICSR criteria in ICH E2D(R1)?
    • A confirmed causal link, a batch number, a prescriber signature, and a laboratory result
    • A product label, a randomized trial, a treatment response, and a safety committee vote
    • A hospital admission, a known dose, a genetic profile, and a published case report
    • An adverse event or other observation, a suspect or interacting product, an identifiable patient, and an identifiable reporter